1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
1 finding from 1 review
QoL · previously untreated patients with mRCC
5 findings from 1 review
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
Show 2 more findings
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
1 finding from 1 review
Death (all causes) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in 1‐year mortality median compared with standard targeted therapies (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Degree of penile curvature · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
1 finding from 1 review
Treatment discontinuation · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
It is very uncertain whether injectional interferon alpha‐2B changes discontinuation from treatment compared with saline (very low certainty).
1 finding from 1 review
Outcomes ( · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported ability to have intercourse · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies showed no clear difference in 1‐year mortality compared with standard targeted therapy (moderate certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (low certainty).
1 finding from 1 review